Description

Overview

PT-141, also known as Bremelanotide, is a synthetic cyclic heptapeptide that belongs to the class of melanocortin receptor agonists. Its ability to interact with the melanocortin-4 receptor (MC4R) and other melanocortin subtypes has positioned it as a key subject of interest in neuropeptide research. Unlike traditional melanocortin peptides, PT-141 exhibits a distinct pharmacological profile, allowing researchers to study the modulation of central melanocortin pathways in controlled experimental models.

Researchers continue to investigate PT-141’s receptor selectivity and structure-activity relationships to better understand how melanocortin signaling contributes to various biological processes. Its cyclic structure enhances receptor binding stability, making it an important model peptide in the study of ligand-receptor dynamics, second messenger cascades, and neuropeptide network interactions.

Areas of Research

• Investigation into melanocortin receptor (MC4R, MC1R) activation and downstream signaling.

• Studies exploring neuropeptide interactions within central regulatory pathways.

• Research into cyclic peptide structure-activity relationships (SAR) for receptor binding affinity.

• Examination of melanocortin receptor selectivity and ligand-induced signaling modulation.

• Studies on the role of melanocortin peptides in neuroendocrine response models.

Notes & Considerations

• PT-141’s cyclic structure enhances its receptor binding stability, making it a valuable model for studying peptide-receptor interactions.

• Researchers are actively investigating how structural modifications to PT-141 influence melanocortin receptor specificity and downstream signaling.

• Comparative studies with other melanocortin peptides (such as α-MSH) have highlighted the role of receptor subtype selectivity in determining physiological responses.

• Ongoing studies are examining potential synergies between PT-141 and other neuropeptides involved in central nervous system regulation.